- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04874701
Effects of Capsimax on Appetite, Energy Intake and Blood Pressure
Obesity is an ongoing major public health problem in most countries of the world for which the agrifood industry still remains criticized because of the abundant offer of high sugar-lipid-energy dense foods, particularly in the fast-food sector. The resulting societal pressure on the food industry probably explains in part the efforts that have been deployed to seek natural active ingredients and to develop functional foods favorably influencing energy balance. Capsaicin is a food non-nutrient constituent that was shown to decrease appetite sensations and subsequent energy intake. The measurement of heart rate variability revealed an association between the increase in sympathetic nervous system (SNS) activity and the satiating effects induced by capsaicin. This is concordant with the observation that pre-prandial intake of capsaicin, be it in capsules or diluted in tomato juice, increased satiety and reduced energy intake.
The objective of this study is to evaluate the long effects of Capsimax on appetite sensations and energy expenditure under conditions of moderate energy restriction and to evaluate the long-term effects of Capsimax on energy intake and expenditure under conditions of moderate energy restriction.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Québec, Canada, G1V0A6
- PEPS-Université Laval
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Premenopausal women
- Between 18 and 50 years
- Healthy
- Non-smoker
- BMI between 25 and 35 kg/m2
- Weight stability
Exclusion Criteria:
- Pregnant or menopausal woman
- History of losing and gaining weight (yo-yo)
- Taking medication for diabetes, hypertension, depression, or hypothyroid
- Taking a supplement for weight loss
- Vegetarian, vegan, intolerant to gluten or pepper (investigational product), and severe allergy to peanuts or nuts
- Suffers from Irritable Bowel Syndrome or gastro-oesophageal reflux
- Suffers from stomach ulcers or inflammation
- Other serious conditions such as cardiovascular, renal, liver, and lung diseases
- History of drug abuse and current alcohol abuse
- Use of any medication (including over-the-counter medications and herbal remedies) such as grapefruit juice, piperine, NSAIDs, etc.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Capsimax
|
Capsimax, 2 capsules per day, for 12 weeks Medicinal ingredient: Capsicum annuum Quantity (per capsule): 100.0 mg
Personalised diet plan targeting a 500 kcal/day energy restriction
|
PLACEBO_COMPARATOR: Placebo
Placebo, 2 capsules per day, for 12 weeks
|
Personalised diet plan targeting a 500 kcal/day energy restriction
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in appetite sensations, energy intake and food preferences at Week 12
Time Frame: 12 weeks
|
Visual analog scales used after a standardized breakfast and a buffet-type meal to measure hunger, fullness, satiety and desire to eat.
|
12 weeks
|
Change from Baseline in energy expenditure at Week 12
Time Frame: 12 weeks
|
Energy expenditure measured at fasting stade, after a 15 minutes rest, by indirect calorimetry
|
12 weeks
|
Change from Baseline in Body weight and fat at Week 12
Time Frame: 12 weeks
|
Body weight and fat measured with Dual-energy X-ray absorptiometry (DXA)
|
12 weeks
|
Change from Baseline in Blood pressure at Week 12
Time Frame: 12 weeks
|
Blood pressure measured every 30 minutes during a 3h testing
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline Microbiota analysis at Week 12
Time Frame: 12 weeks
|
Sequencing of the 16S DNA to evaluate the evolution of the microbiota according to the diet.
|
12 weeks
|
Change from Baseline System analysis of endocannabinoids at Week 12
Time Frame: 12 weeks
|
The evaluation of the endocannabinoid system done on OpenArray TaqMan according to the expression in RNA of about fifty genes of this system and by their quantification by HPLC coupled to MS / MS mass spectrometry and / or by ion capture.
IT-TOF
|
12 weeks
|
Change from Baseline sleeping quality (PSQI) at Week 12
Time Frame: 12 weeks
|
The Pittsburgh Sleep Quality Index (PSQI) is a validated questionnaire which evaluates sleep quality and disturbance over a 1-month time interval. The PSQI gives a score for seven different components : subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping. medication, and daytime dysfunction |
12 weeks
|
Change from Baseline Feeding behaviors (TFEQ and Food cravings questionnaire) at Weeks 12
Time Frame: 12 weeks
|
Feeding behaviors measured by two validated questionnaires : The Three Factor Eating Questionnaire (TFEQ) which measures three main dimensions of human eating behaviors such as cognitive restraint, disinhibition and susceptibility for hunger and the Food cravings questionnaire
|
12 weeks
|
Change from Baseline anxiety (BDI and STAI) at Week 12
Time Frame: 12 weeks
|
The State-Trait Anxiety Inventory (STAI) is a commonly used measure of trait and state anxiety.
It can be used in clinical settings to diagnose anxiety and to distinguish it from depressive syndromes.
The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Angelo Tremblay, Laval University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAPSIMAX
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
-
Consorcio Centro de Investigación Biomédica en...Maimónides Biomedical Research Institute of Córdoba; Instituto de Salud Carlos... and other collaboratorsActive, not recruiting
-
University of HoustonBaylor College of MedicineCompleted
Clinical Trials on Capsimax
-
Vedic Lifesciences Pvt. Ltd.Completed
-
Pennington Biomedical Research CenterOmniActive Health TechnologiesCompletedEating | Hunger | Energy MetabolismUnited States
-
University of Prince Edward IslandOmniActive Health TechnologiesWithdrawn